Previous 10 | Next 10 |
The following slide deck was published by Charles River Laboratories International, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Charles River Laboratories International, Inc. 2021 Q4 - Results - Earnings Call Presentation
Charles River Laboratories press release (NYSE:CRL): Q4 Non-GAAP EPS of $2.49 beats by $0.06. Revenue of $905.05M (+14.4% Y/Y) beats by $16.78M. Reaffirms 2022 Guidance: Revenue growth 13.0% – 15.0%, Impact of 53rd week in 2022 ~(1.5%), Revenue growth, organic 12.5% ...
– Fourth-Quarter Revenue of $905.1 Million and Full-Year Revenue of $3.54 Billion – – Fourth-Quarter GAAP Earnings per Share of $2.67 and Non-GAAP Earnings per Share of $2.49 – – Full-Year GAAP Earnings per Share of $7.60 and Non-GAAP...
Charles River Laboratories (NYSE:CRL) is scheduled to announce Q4 earnings results on Wednesday, Feb. 16, before market open. The consensus EPS estimate is $2.43 (+1.7% Y/Y) and the consensus revenue estimate is $888.27M (+12.3% Y/Y). Over the last 2 years, CRL has beaten EPS estimates 100% o...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We were opportunistic in the face of recent market volati...
By 2023, 90% of all global electricity for Charles River will be supplied by renewable energy Charles River Laboratories International, Inc. (NYSE: CRL) today announced a wind energy contract with Repsol to address the entirety of the Company’s European power requirem...
Provides Greater Access to Label-Free High-Throughput Screening Solutions Charles River Laboratories International, Inc . (NYSE: CRL) today announced the expansion of their strategic partnership with Chicago, Illinois-based SAMDI Tech, Inc . Under the existing partne...
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2021 financial results on Wednesday, February 16 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 16 th , at ...
Multiyear partnership will leverage Valo’s Opal Computational Platform to accelerate drug discovery and development Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC (“Valo”), the technology company using human-centric data ...
David R. Smith, Corporate Executive Vice President & Chief Financial Officer, to Transition Role by End of 2022 Charles River Issues 2022 Financial Guidance in Conjunction with J.P. Morgan Healthcare Conference Charles River Laboratories International, In...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...